Process for the Asymmetric Epoxidation of Olefins

ABSTRACT

The present invention relates to a catalyst based on ruthenium complexes and to a process for the asymmetric epoxidation of olefins using catalysts based on ruthenium complexes.

This application is a divisional of U.S. patent application Ser. No.11/051,279 filed Feb. 4, 2005, entitled “Process for the AsymmetricEpoxidation of Olefins”, the contents of which are hereby incorporatedby reference in their entirety.

FIELD OF THE INVENTION

The present invention relates to a catalyst based on ruthenium complexesand to a process for the asymmetric epoxidation of olefins usingcatalysts based on ruthenium complexes.

BACKGROUND OF THE INVENTION

Olefins are readily available and inexpensive raw materials forindustrial applications. They can be converted by oxidation intoepoxides which are in turn of great importance as versatileintermediates in the synthesis of active compounds and fine chemicals(cosmetics industry, polymer industry, etc). Chiral epoxides areparticularly valuable since they make it possible to obtain numerousstructural elements, e.g. chiral diols or chiral amino alcohols, whichfrequently occur, in particular, in natural products and biologicallyactive compounds. The most efficient and most economical method ofsynthesizing chiral epoxides is the catalytic, asymmetric epoxidation ofolefins.

Mezefti et al. (Green Chemistry 1999, 1, 39-41; Organometallics 2000,19, 4117-4126) discloses that olefins can be epoxidized in the presenceof ruthenium catalysts and using hydrogen peroxide as oxidant, but theenantioselectivities of at most 42% are unsatisfactory and the yieldsare in most cases too low for industrial applications.

Other ruthenium-based systems, e.g. chiral Schiff-base complexes(Kureshi et al., J. Mol. Catal. A: Chemical 1997, 124, 91-97) arelikewise quite inefficient in terms of yield and stereoselectivity.

A further process has been described by Nishiyama et al. (Chem. Commun.1997, 1863-1864). In the epoxidation of trans-stilbene,enantioselectivities of 74% at yields of up to 63% were achieved usingruthenium-pyridine-2,6-dicarboxylate complexes having chiralbis(oxazolinyl)pyridine ligands. However, a disadvantage of this processis that bis(acetoxy)iodobenzene has to be used as reoxidant. Thisreagent is unattractive for industrial processes because of its highprice.

There is therefore still a need to develop a general and efficientprocess for the asymmetric epoxidation of olefins, which displays highchemoselectivities and enantioselectivities and also gives good productyields. At the same time, the use of a both inexpensive andenvironmentally friendly oxidant is desirable from an industrial pointof view.

SUMMARY OF THE INVENTION

We have now found a process for preparing stereoisomerically enrichedcompounds of the formula (I),

where

-   “*” is a carbon atom having an (R) or (S) configuration and R¹, R²,    R³ and R⁴ are each, independently of one another, hydrogen, alkyl,    aryl, arylalkyl, haloalkyl or a radical of one of formulae (IIa) to    (IIf)

A-B-D-E  (IIa)

A-E  (IIb)

A-SO₂-E  (IIc)

A-B-SO₂R⁶  (IId)

A-SO₃W  (IIe)

A-COW  (IIf)

where, in the formulae (IIa) to (IIf)

-   A is absent or is an alkylene or haloalkylene radical and-   B is absent or is oxygen or NR⁵, where-   R⁵ is nitrogen, arylalkyl or aryl, and-   D is a carbonyl group and-   E is R⁶, OR⁶, NHR⁷ or N(R⁷)₂,-   where-   R⁶ is alkyl, arylalkyl or aryl and-   the radicals R⁷ are each, independently of one another, alkyl,    arylalkyl or aryl or the moiety N(R⁷)₂ is a cyclic amino radical    having from 4 to 12 carbon atoms and-   W is OH, NH₂, or OM, where M is an alkali metal ion, half an    equivalent of an alkaline earth metal ion, an ammonium ion or an    organic ammonium ion,    or two of the radicals R¹, R², R³ and R⁴ are together part of a 3-    to 7-membered ring having a total of from 3 to 16 carbon atoms,    which is characterized in that compounds of the formula (III),

where R¹, R², R³ and R⁴ are each, independently of one another, asdefined above,are reacted with compounds of the formula (IV),

R⁸—OOH  (IV)

where R⁸ is hydrogen, alkyl or arylalkyl,with the reaction being carried out in the presence of a rutheniumcomplex which bears as ligands both compounds of the formula (V)

where R⁹ is hydrogen, halogen, hydroxy, hydroxycarbonyl, alkoxycarbonyl,alkoxy, alkyl, arylalkyl or aryl andL¹ and L² are each, independently of one another, a radical of theformula (VI-a) or a radical of the formula (VI-b), but are preferablyidentical radicals of the formula (VI-a) or of the formula (VI-b)

where “*1” and/or “*2” and/or “*3” are each an asymmetric carbon atom inthe (R) or (S) configuration, with preference being given to “*1” beingan asymmetric carbon atom in the (R) or (S) configuration and “*2”and/or “*3” likewise being able to be such a carbon atom, the arrowpoints to the point of bonding to the central pyridine ring and R^(10a),R^(10b) and R¹¹ are each, independently of one another, alkyl,alkoxyalkyl, trialkylsiloxyalkyl, alkoxycarbonyl, arylalkyl or aryl orR^(10a) and R¹¹ or R^(10a) and R^(10b) are part of a cyclic radicalhaving a total of from 5 to 16 carbon atoms and R¹¹ and/or in each caseone or both radicals R^(10a) and/or R^(10b), preferably in each case oneor both radicals R^(10a) and/or R^(10b), may also be hydrogen,and compounds of the formula (VII)

where

-   X¹, X² and X³ are each, independently of one another, N, CH or CR¹²    and-   R¹² is hydrogen, halogen, hydroxy, hydroxycarbonyl, alkoxycarbonyl,    alkoxy, alkoxyalkyl, arylalkyl or aryl and-   n is 0, 1, 2 or 3, preferably 0 or 1 and more preferably 0.

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of the invention, stereoisomerically enriched meansthat one diastereomer or enantiomer is present in a higher relativeproportion than the other diastereomers or the other enantiomer.

The present invention encompasses all definitions of radicals,parameters and explanations above and below, in general terms or inpreferred ranges, in any combination with one another, i.e. also betweenthe respective ranges and preferred ranges.

For the purposes of the present invention, aryl preferably refers,unless indicated individually, to carbocyclic aromatic radicals havingfrom 6 to 24 skeletal carbon atoms or heteroaromatic radicals havingfrom 5 to 24 skeletal carbon atoms in which no, one, two or threeskeletal carbon atoms per ring, but at least one skeletal carbon atom inthe total molecule, can be replaced by heteroatoms selected from thegroup consisting of nitrogen, sulphur and oxygen. Furthermore, thecarbocyclic aromatic radicals or heteroaromatic radicals can besubstituted by up to five identical or different substituents per ringselected from the group consisting of hydroxy, fluorine, nitro, cyano,free or protected formyl, C₁-C₁₂-alkyl, C₅-C₁₄-aryl, C₆-C₁₅-arylalkyl,—PO—[(C₁-C₈)-alkyl]₂, —PO—[(C₅-C₁₄)-aryl]₂,—PO—[(C₁-C₈)-alkyl)(C₅-C₁₄)-aryl)], tri(C₁-C₈-alkyl)siloxyl or radicalsof the formulae (IIa) to (IIf). The same applies to the aryl part of anarylalkyl radical.

For example, aryl is preferably phenyl, naphthyl or anthracenyl whichmay be substituted by one, two or three radicals selected independentlyfrom the group consisting of C₁-C₆-alkyl, C₅-C₁₄-aryl, C₁-C₆-alkoxy,C₁-C₆-alkoxycarbonyl, halogen, hydroxy, nitro or cyano.

For the purposes of the present invention alkyl or alkylene or alkoxy ispreferably, unless indicated individually, in each case independently, astraight-chain, cyclic, branched or unbranched alkyl or alkylene oralkoxy radical which may be further substituted by C₁-C₄-alkoxyradicals. The same applies to the alkylene part of an arylalkyl radical.

For example, alkyl is preferably methyl, ethyl, n-propyl, isopropyl,n-butyl, tert-butyl, n-pentyl, cyclohexyl and n-hexyl, n-heptyl,n-octyl, isooctyl, n-decyl and n-dodecyl.

For example, alkylene is preferably methylene, 1,1-ethylene,1,2-ethylene, 1,1-propylene, 1,2-propylene, 1,3-propylene, 1,1-butylene,1,2-butylene, 2,3-butylene and 1,4-butylene, 1,5-pentylene,1,6-hexylene, 1,1-cyclohexylene, 1,4-cyclohexylene, 1,2-cyclohexyleneand 1,8-octylene.

For example, alkoxy is preferably methoxy, ethoxy, isopropoxy,n-propoxy, n-butoxy, tert-butoxy and cyclohexyloxy.

For the purposes of the present invention, arylalkyl is preferably,unless indicated individually, in each case independently, astraight-chain, cyclic, branched or unbranched alkyl radical which maybe monosubstituted or polysubstituted, more preferably monosubstituted,by aryl radicals as defined above.

For the purposes of the present invention, haloalkyl or haloalkylene ispreferably, unless indicated individually, in each case independently, astraight-chain, cyclic, branched or unbranched alkyl radical which maybe monohalogenated, polyhalogenated or perhalogenated by halogen atomsselected independently from the group consisting of fluorine, chlorine,bromine and iodide.

For example, C₁-C₈-haloalkyl is preferably trifluoromethyl,trichloromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl andnonafluorobutyl; C₁-C₈-fluoroalkyl is trifluoromethyl,2,2,2-trifluoroethyl, pentafluoroethyl and nonafluorobutyl.

Protected formyl is a formyl radical which is protected by conversioninto an aminal, acetal or a mixed aminal-acetal, with the aminals,acetals and mixed aminal-acetals being able to be acyclic or cyclic.

Preferred compounds of the formulae (I), (IV), (V) and (VII) are definedbelow.

In the formula (I), R¹, R², R³ and R⁴ are each preferably, independentlyof one another, hydrogen, C₁-C₈-alkyl, C₅-C₁₄-aryl, C₆-C₁₅-arylalkyl,C₁-C₈-haloalkyl or two of the radicals R¹, R², R³ and R⁴ are togetherpart of a 3- to 7-membered ring having a total of from 3 to 16 carbonatoms.

More preference is given to compounds in which at least one, even morepreferably at least two, radicals R¹, R², R³ and R⁴ are hydrogen.

In the formula (IV), R⁸ is preferably hydrogen or C₃-C₆-alkyl, morepreferably hydrogen or tert-butyl and most preferably hydrogen.

In the formula (V), R⁹ is preferably hydrogen, halogen, C₁-C₄-alkoxy,C₁-C₄-alkyl, phenyl, more preferably hydrogen or phenyl.

Furthermore, L¹ and L² in the formula (V) are identical radicals of theformula (VI-a) or (VI-b).

Preference is given to the radicals R^(10a) and/or R^(10b) each being,independently of one another, hydrogen, methyl or phenyl. Particularpreference is given to in each case one of the radicals R^(10a) and/orR^(10b) being methyl or phenyl and the second radical R^(10a) and/orR^(10b) and, if applicable, the two other radicals R^(10a) or R^(10b)being hydrogen, or one radical R^(10a) being hydrogen and the secondradical R^(10a) together with R¹¹ forming an indanediyl group. Morepreferably, R^(10a) in the formula (VI-a) and R^(10a) and R^(10b) in theformula (VI-b) are each hydrogen.

The radical R¹¹ is preferably methyl, isopropyl, tert-butyl, 2-naphthyl,phenyl, 2-chlorophenyl, benzyl, hydroxymethyl, tributylsiloxymethyl,2-tributylsiloxyethyl or methoxycarbonyl.

In compounds of the formula (VII), R¹² is preferably hydrogen, hydroxy,C₁-C₄-alkoxy or phenyl, more preferably hydrogen.

Preference is given to at least two, preferably three, of the radicalsX¹, X², X³ being CH or CR¹².

n is preferably 0 or 1 and more preferably denotes one substitutent inthe 4 position.

Preferred ruthenium complexes are complexes of the formula (VIII)

[Ru(V)(VII)]  (VIII)

where (V) denotes a compound of the formula (V) and (VII) denotes acompound of the formula (VII). Such complexes can be prepared in amanner known per se by methods analogous to those described in thereferences cited at the outset.

Compounds of the formula (V) are, with the exception of compounds inwhich L¹ and L² are each a radical of the formula (VI-a), where theradicals R^(10a) are each hydrogen and R¹¹ is isopropyl or phenyl,previously unknown and are therefore encompassed by the presentinvention. The same applies to the ruthenium complexes which are used inthe process of the invention and are derived from such compounds of theformula (V), such as ruthenium complexes of the formula (VIII).

Examples of such compounds of the formula (V) are4-Chloro-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine,4-phenyl-2,6-bis[4′-(S)-phenyl-oxazolin-2′-yl]pyridine,2,6-bis[(R)-4′-(1″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridineand2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine.

Compounds of the formula (V) can be prepared, for example, by the methodof Nishiyama et al., Organometallics 1991, 10, 500-508.

Preferably, the process of the invention is carried out in the presenceof organic solvents, in particular secondary or tertiary alcohols,aprotic polar solvents, ketones, chlorinated hydrocarbons and aromatichydrocarbons. For the purposes of the present invention, aprotic polarsolvents are solvents which have a dielectric constant at 25° C. of 5 ormore and a pK_(a) based on an aqueous reference scale at 25° C. of 20 ormore. Particular preference is given to using secondary and tertiaryalcohols, in particular t-amyl alcohol and t-butyl alcohol, in theprocess of the invention.

The reaction is, for example, carried out by placing the compounds ofthe formula (III) and the ruthenium complex and, if appropriate, anadditive together with an organic solvent in a reaction vessel andadding the oxidant, if appropriate as a solution in a suitable organicsolvent. In a preferred embodiment, a solution of the oxidant is meteredinto the reaction mixture over a period of from 10 minutes to 24 hours.

The reaction time (further stirring time) can be, for example, up to 24hours, preferably up to 5 hours and preferably up to 2 hours.

The reaction can be carried out at temperatures of from −20° C. to 150°C., preferably from 0 to 80° C., more preferably from 0° C. to 40° C.,and most preferably from 15° C. to 30° C.

The pressure in the reaction is not critical and can be, for example,from 0.5 to 100 bar, preferably from 0.8 to 10 bar. More preference isgiven to ambient pressure.

As compounds of the formula (IV), preference is given to usingtert-butyl hydroperoxide or hydrogen peroxide in the process of theinvention. The oxidant is preferably used in an amount of from 1 to 10molar equivalents based on compounds of the formula (III), morepreferably from 1 to 5 molar equivalents and most preferably from 1 to 3molar equivalents. It may be advantageous to use the oxidant as asolution in a solvent, preferably as a solution in water.

According to the process of the present invention, additives can beadded to the reaction mixture. Examples of suitable additives include:amines, phosphites, phosphine oxides, N-methylmorpholine N-oxide,2,2,6,6-tetramethylpiperidin-1-yl oxide, pyridines, pyridine N-oxide,imidazoles, quinoline, quinoline N-oxide, 2,2′-bipyridyl, 2,2′-bipyridylN,N′-dioxide, ammonium salts, aromatic and aliphatic carboxylic acids,carboxylic anhydrides, (R)- or (S)-alkanesulfinamides and aromaticalcohols. These additives are preferably used in an amount of from 5 to100 mol % based on compounds of the formula (III), more preferably from10 to 50 mol % and very most preferably 20 mol %.

For the purposes of the present invention, the ruthenium complex caneither be used as an isolated complex or be generated in situ in thereaction mixture. In the latter case, a suitable ruthenium precursor

complex, e.g. [Ru(p-cymene)Cl₂]₂, and the two ligands of the formulae(V) and (VII) are combined in the reaction mixture.Isolated complexes are, for example,

-   [Ru(4-chloro-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]-   [Ru(4-phenyl-2,6-bis[4′-(S)-phenyloxazolin-2-yl]pyridine)    (pyridine-2,6-dicarboxylate)]-   [Ru(2,6-bis[4′-(S)-isopropyloxazoline-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]-   [Ru(2,6-bis[(R)-4′-phenyl-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]-   [Ru(2,6-bis[(R)-4′-(1″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]-   [Ru(2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]

The preparation of the isolated complexes is preferably likewise carriedout by combining a suitable ruthenium precursor complex such as[Ru(p-cymene)Cl₂]₂, and the two ligands of the formulae (V) and (VIII)by, for example, introducing the ruthenium precursor complex with theligand of the formula (V) into a suitable solvent in an inert gasatmosphere and adding a solution of the ligand of the formula (VII),subsequently heating the reaction mixture and isolating the rutheniumcomplex after work-up by means of extraction, drying and optionallysubsequent chromatographic purification and/or recrystallization.

For the purposes of the present invention, the amount of rutheniumcomplex used or of ruthenium precursor complex used is, for example, inthe range from 0.01 to 20 mol %, preferably from 1 to 10 mol % and morepreferably from 2 to 5 mol %.

Compounds of the formula (I) can be obtained in good yields with highstereoisomeric or enantiomeric excesses in the manner prescribed by theinvention. The work-up can be carried out in a known manner, e.g. byquenching with water, extraction with a suitable organic solvent anddistillation or recrystallization of the epoxide.

The compounds of the formula (I) which can be prepared according to theinvention are particularly useful for preparing pharmaceuticals,agrochemicals, polymers or intermediates for these.

In the process of the present invention, the asymmetric epoxidation ofolefins proceeds with high chemoselectivity and enantioselectivity andgives very good product yields. At the same time, the ability to use theinexpensive oxidant hydrogen peroxide is a particular advantage.

EXAMPLES General Method

In a typical experiment, an olefin (0.5 mmol) and the ruthenium complexcatalyst[Ru(S,S-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)](0.025 mmol) were admixed with t-amyl alcohol (9 ml) and an additive wasadded if applicable. A solution of the oxidant (0.75 mmol) in t-amylalcohol (1 ml) was metered into this mixture over a period of 12 hours.After the reaction was complete (monitoring of the conversion byGC-FID), the reaction mixture was quenched with saturated Na₂SO₃solution (about 10 ml) and extracted twice with dichloromethane (10 mleach time). After removal of the solvent by distillation, the productwas purified by column chromatography. All products described below wereconfirmed by GC-MS and NMR data and comparison with authentic samples(GC-FID).

Example 1

Use of trans-stilbene and H₂O₂ as oxidant in the general method gavetrans-stilbene oxide in a yield of 99% and an ee of 67%.

Example 2

Use of trans-stilbene and H₂O₂ as oxidant in the presence of 0.025 mmolof 2,2′-bipyridyl N,N′-dioxide as additive in the general method gavestilbene oxide in a yield of 96% and an ee of 71%.

Example 3

Use of trans-stilbene and H₂O₂ as oxidant and the catalyst[Ru(4-chloro-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]in the general method gave trans-stilbene oxide in a yield of 93% and anee of 71%.

Example 4

Use of trans-stilbene and H₂O₂ as oxidant and the catalyst[Ru(4-phenyl-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)] (0.025 mmol) in the general method gavetrans-stilbene oxide in a yield of 97% and an ee of 69%.

Example 5

Use of trans-stilbene and H₂O₂ as oxidant and the catalyst[Ru(2,6-bis[4′-(S)-isopropyloxazolin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)](0.025 mmol) in the general method gave trans-stilbene oxide in a yieldof 100% and an ee of 54%.

Example 6

Use of styrene and H₂O₂ as oxidant in a procedure analogous to Example 1gave styrene oxide in a yield of 71% and an ee of 31%.

Example 7

Use of styrene and H₂O₂ as oxidant and acetic acid in a procedureanalogous to Example 1 gave styrene oxide in a yield of 75% and an ee of42%.

Example 8

Use of p-chlorostyrene and t-BuOOH as oxidant in a procedure analogousto Example 1 gave p-chlorostyrene oxide in a yield of 48% and an ee of34%.

Example 9

Use of p-fluorostyrene and t-BuOOH as oxidant in a procedure analogousto Example 1 gave p-fluorostyrene oxide in a yield of 54% and an ee of34%.

Example 10

Use of α-methylstyrene and H₂O₂ as oxidant in a procedure analogous toExample 1 gave α-methylstyrene oxide in a yield of 52% and an ee of 13%.

Example 11

Use of β-methylstyrol and H₂O₂ as oxidant in a procedure analogous toExample 1 gave β-methylstyrene oxide in a yield of 82% and an ee of 58%.

Example 12

Use of 2-methyl-1-phenyl-1-propene and t-BuOOH as oxidant in a procedureanalogous to Example 1 gave 2-methyl-1-phenyl-1-propene oxide in a yieldof 95% and an ee of 65%.

Example 13

Use of 1,2-diphenyl-1-propene and t-BuOOH as oxidant in the generalmethod gave 1,2-diphenyl-1-propene oxide in a yield of 93% and an ee of22%.

Example 14

Use of triphenylethylene and t-BuOOH as oxidant in a procedure analogousto Example 1 gave triphenylethylene oxide in a yield of 90% and an ee of8%.

Example 15

Use of 1-phenylcyclohexene and H₂O₂ as oxidant in a procedure analogousto Example 1 gave 1-phenylcyclohexene oxide in a yield of 87% and an eeof 12%.

Example 16

Use of trans-stilbene and H₂O₂ as oxidant in a procedure analogous toExample 1, but with generation of the catalyst in situ from 0.0125 molof [Ru(p-cymene)Cl₂]₂, 0.025 mol of2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine and 0.025 mol of disodiumpyridine-2,6-dicarboxylate, gave trans-stilbene oxide in a yield of 96%and an ee of 61%.

TABLE 1 Tabular summary of Examples 1 to 16 of the asymmetricepoxidation of olefins in the presence of ruthenium complexes

Yield ee Ex. Olefin Oxidant Additive Catalyst [%] [%] 1

H₂O₂ — R¹¹ = Ph; R⁹ = H; R¹² = H 99 67 2

H₂O₂ 5 mol % of 2,2′- bipyri- dyl N,N′- oxide R¹¹ = Ph; R⁹ = H; R¹² = H96 71 3

H₂O₂ — R¹¹ = Ph; R⁹ = Cl; R¹² = H 93 71 4

H₂O₂ — R¹¹ = Ph; R⁹ = Ph; R¹² = H 97 69 5

H₂O₂ — R¹¹ = i-Pr; R¹² = R⁹ = H 100 54 6

H₂O₂ — R¹¹ = Ph; R¹² = R⁹ = H 71 31 7

H₂O₂ 20 mol % of acetic acid R¹¹ = Ph; R¹² = R⁹ = H 75 42 8

t-BuOOH — R¹¹ = Ph; R¹² = R⁹ = H 48 34 9

t-BuOOH — R¹¹ = Ph; R¹² = R⁹ = H 54 34 10

H₂O₂ — R¹¹ = Ph; R¹² = R⁹ = H 52 13 11

H₂O₂ — R¹¹ = Ph; R¹² = R⁹ = H 82 58 12

t-BuOOH — R¹¹ = Ph; R¹² = R⁹ = H 95 65 13

t-BuOOH — R¹¹ = Ph; R¹² = R⁹ = H 93 22 14

t-BuOOH — R¹¹ = Ph; R¹² = R⁹ = H 90 8 15

H₂O₂ — R¹¹ = Ph; R¹² = R⁹ = H 87 12 16

H₂O₂ — R¹¹ = Ph R¹² = R⁹ = H; in situ generation. 96 61

Example 17

Use of styrene and H₂O₂ as oxidant and the catalyst[Ru(2,6-bis[(R)-4′-phenyl-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)](0.025 mmol) in the general method gave styrene oxide in a yield of 56%and an ee of 48%.

Example 18

Use of styrene and H₂O₂ as oxidant and the catalyst[Ru(2,6-bis[(R)-4′-(1″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)](0.025 mmol) in the general method gave styrene oxide in a yield of 65%and an ee of 38%.

Example 19 Preparation of[Ru(2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)]

A solution of 64 mg of disodium pyridine-2,6-dicarboxylate (0.30 mmol)in 2 ml of a mixture of methanol/water (1:1) was added dropwise under anAr atmosphere to a solution of 150 mg of2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine(0.30 mmol) and 92 mg of [Ru(p-cymene)Cl₂]₂ (0.15 mmol) in 2 ml ofmethanol and the reaction mixture was heated at 65° C. for 1 hour. Thereaction mixture was subsequently extracted with 30 ml of CH₂Cl₂, theorganic phase was washed with 30 ml of water, dried over MgSO₄, filteredand the solvent was removed under reduced pressure. After subsequentchromatography over silica gel (70-230 mesh) using CH₂Cl₂/methanol (from100:2 to 100:5) as gradated eluent and renewed removal of the solventunder reduced pressure, the product was recrystallized fromCH₂Cl₂/n-hexane. This gave 138 mg of[Ru(2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)] (60% of theory).

Example 20

Use of styrene and H₂O₂ as oxidant and the catalyst[Ru(2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine)(pyridine-2,6-dicarboxylate)](0.025 mmol) in the general method gave styrene oxide in a yield of 59%and an ee of 48%.

Ex- Oxi- Yield ee ample Olefin dant Additive Catalyst [%] [%] 17

H₂O₂ — R¹¹ = Ph; R⁹ = H; R¹² = H 56 48 18

H₂O₂ — R¹¹ = 1-naphthyl; R⁹ = H; R¹² = H 65 38 20

H₂O₂ — R¹¹ = 2-naphthyl; R⁹ = H; R¹² H 59 48

Although the invention has been described in detail in the foregoing forthe purpose of illustration, it is to be understood that such detail issolely for that purpose and that variations can be made therein by thoseskilled in the art without departing from the spirit and scope of theinvention except as it may be limited by the claims.

1. Compounds according to formula (V) comprising:

wherein R⁹ is hydrogen, halogen, hydroxy, alkoxy, hydroxycarbonyl,alkoxycarbonyl, alkyl, arylalkyl or aryl and L¹ and L² are each,independently of one another, a radical of the formula (VI)

wherein “*1” is an asymmetric carbon atom in the (R) or (S)configuration and “*2” can likewise be such a carbon atom, the arrowpoints to the point of bonding to the central pyridine ring and each R¹⁰and R¹¹ are each, independently of one another, alkyl, alkoxyalkyl,trialkylsiloxyalkyl, alkoxycarbonyl, arylalkyl or aryl or one R¹⁰ andR¹¹ are part of a cyclic radical having a total of from 5 to 16 carbonatoms and the other R¹⁰ is hydrogen said compound not including thoseradicals where L¹ and L² are radicals where both R¹⁰ are each hydrogenand R¹¹ is isopropyl or phenyl.
 2. Compounds according to claim 1consisting of those selected from4-Chloro-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine,4-phenyl-2,6-bis[4′-(S)-phenyl-oxazolin-2′-yl]pyridine,2,6-bis[(R)-4′-(1″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine,and2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]-pyridine.3. Ruthenium complexes comprising compounds of the formula (V) accordingto claim
 1. 4. Ruthenium complexes according to claim 3 consisting ofthose selected from4-Chloro-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine,4-phenyl-2,6-bis[4′-(S)-phenyloxazolin-2′-yl]pyridine,2,6-bis[(R)-4′-(1″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine,and2,6-bis[(R)-4′-(2″-naphthyl)-5′,6′-dihydro-4′H-[1′,3′]oxazin-2′-yl]pyridine.5. Method of for preparing pharmaceuticals, agrochemicals, polymers orintermediates comprising preparing said pharmaceuticals, agrochemicals,polymer or intermediates by using compounds of the formula (I)

wherein “*” is a carbon atom having an (R) or (S) configuration and R¹,R², R³ and R⁴ are each, independently of one another, hydrogen, alkyl,aryl, arylalkyl, haloalkyl or a radical of one of formulae (IIa) to(IIf)A-B-D-E  (IIa)A-E  (IIb)A-SO₂-E  (IIc)A-B-SO₂R⁶  (IId)A-SO₃W  (IIe)A-COW  (IIf) wherein, in the formulae (IIa) to (IIf) A is absent or isan alkylene or haloalkylene radical and B is absent or is oxygen or NR⁵,where R⁵ is nitrogen, arylalkyl or aryl, and D is a carbonyl group and Eis R⁶, OR⁶, NHR⁷ or N(R⁷)₂, wherein R⁶ is alkyl, arylalkyl or aryl andthe radicals R⁷ are each, independently of one another, alkyl, arylalkylor aryl or the moiety N(R⁷)₂ is a cyclic amino radical having from 4 to12 carbon atoms and W is OH, NH₂, or OM, where M is an alkali metal ion,half an equivalent of an alkaline earth metal ion, an ammonium ion or anorganic ammonium ion, or two of the radicals R¹, R², R³ and R⁴ aretogether part of a 3- to 7-membered ring having a total of from 3 to 16carbon atoms, wherein compounds of formula (I) are prepared by reactingcompounds of the formula (III),

where R¹, R², R³ and R⁴ are each, independently of one another, asdefined above, with compounds of the formula (IV),R⁸—OOH  (IV) wherein R⁸ is hydrogen, alkyl or arylalkyl, in the presenceof a ruthenium complex which bears as ligands both compounds of theformula (V)

wherein R⁹ is hydrogen, halogen, hydroxy, alkoxy, hydroxycarbonyl,alkoxycarbonyl, alkyl, arylalkyl or aryl and L¹ and L² are each,independently of one another, a radical of the formula (VI)

wherein “*1” is an asymmetric carbon atom in the (R) or (S)configuration and “*2” can likewise be such a carbon atom, the arrowpoints to the point of bonding to the central pyridine ring and R¹⁰ andR¹¹ are each, independently of one another, alkyl, alkoxyalkyl,trialkylsiloxyalkyl, alkoxycarbonyl, arylalkyl or aryl or R¹⁰ and R¹¹are part of a cyclic radical having a total of from 5 to 16 carbon atomsand R¹⁰ may also be hydrogen, and compounds of the formula (VII)

wherein X¹, X² and X³ are each, independently of one another, N, CH orCR¹² and R¹² is hydrogen, halogen, hydroxy, hydroxycarbonyl,alkoxycarbonyl, alkoxy, alkoxyalkyl, arylalkyl or aryl and n is 0, 1, 2or 3, preferably 0 or 1 and particularly preferably
 0. 6. Apharmaceutical comprising a compound of the formula (I) preparedaccording to claim
 5. 7. An agrochemical comprising a compound of theformula (I) prepared according to claim
 5. 8. A polymer comprising acompound of the formula (I) prepared according to claim
 5. 9. Anintermediate compound for a pharmaceutical, an agro chemical or apolymer comprising a compound of the formula (I) wherein the compound offormula (I) wherein compounds of formula (I):

wherein “*” is a carbon atom having an (R) or (S) configuration and R¹,R², R³ and R⁴ are each, independently of one another, hydrogen, alkyl,aryl, arylalkyl, haloalkyl or a radical of one of formulae (IIa) to(IIf)A-B-D-E  (IIa)A-E  (IIb)A-SO₂-E  (IIc)A-B-SO₂R⁶  (IId)A-SO₃W  (IIe)A-COW  (IIf) wherein, in the formulae (IIa) to (IIf) A is absent or isan alkylene or haloalkylene radical and B is absent or is oxygen or NR⁵,where R⁵ is nitrogen, arylalkyl or aryl, and D is a carbonyl group and Eis R⁶, OR⁶, NHR⁷ or N(R⁷)₂, wherein R⁶ is alkyl, arylalkyl or aryl andthe radicals R⁷ are each, independently of one another, alkyl, arylalkylor aryl or the moiety N(R⁷)₂ is a cyclic amino radical having from 4 to12 carbon atoms and W is OH, NH₂, or OM, where M is an alkali metal ion,half an equivalent of an alkaline earth metal ion, an ammonium ion or anorganic ammonium ion, or two of the radicals R¹, R², R³ and R⁴ aretogether part of a 3- to 7-membered ring having a total of from 3 to 16carbon atoms, are prepared by reacting compounds of the formula (III),

where R¹, R², R³ and R⁴ are each, independently of one another, asdefined above, with compounds of the formula (IV),R⁸—OOH  (IV) wherein R⁸ is hydrogen, alkyl or arylalkyl, in the presenceof a ruthenium complex which bears as ligands both compounds of theformula (V)

wherein R⁹ is hydrogen, halogen, hydroxy, alkoxy, hydroxycarbonyl,alkoxycarbonyl, alkyl, arylalkyl or aryl and L¹ and L² are each,independently of one another, a radical of the formula (VI)

wherein “*1” is an asymmetric carbon atom in the (R) or (S)configuration and “*2” can likewise be such a carbon atom, the arrowpoints to the point of bonding to the central pyridine ring and R¹⁰ andR¹¹ are each, independently of one another, alkyl, alkoxyalkyl,trialkylsiloxyalkyl, alkoxycarbonyl, arylalkyl or aryl or R¹⁰ and R¹¹are part of a cyclic radical having a total of from 5 to 16 carbon atomsand R¹⁰ may also be hydrogen, and compounds of the formula (VII)

wherein X¹, X² and X³ are each, independently of one another, N, CH orCR¹² and R¹² is hydrogen, halogen, hydroxy, hydroxycarbonyl,alkoxycarbonyl, alkoxy, alkoxyalkyl, arylalkyl or aryl and n is 0, 1, 2or 3, preferably 0 or 1 and particularly preferably 0.